Cargando…

Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators

INTRODUCTION: Ventilator-associated pneumonia (VAP) is associated with increased medical resource utilization, but few randomized studies have been conducted to evaluate the effect of initial antibiotic therapy. To assess medical resource utilization in patients with VAP, we conducted a pooled analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kollef, Marin H, Nathwani, Dilip, Merchant, Sanjay, Gast, Christopher, Quintana, Alvaro, Ketter, Nzeera
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911715/ https://www.ncbi.nlm.nih.gov/pubmed/20459721 http://dx.doi.org/10.1186/cc9012

Ejemplares similares

A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia
por: Kollef, Marin H, et al.
Publicado: (2012)

Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial
por: Lodise, Thomas, et al.
Publicado: (2020)

Polymyxins and Doripenem Combination Against KPC-Producing Klebsiella pneumoniae
por: Lee, Grace C., et al.
Publicado: (2013)

Doripenem in the Treatment of Patients with Nosocomial Pneumonia: A Meta-Analysis
por: Huang, Chienhsiu, et al.
Publicado: (2022)

Determinants of Mortality for Ventilated Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
por: Motowski, Hayley, et al.
Publicado: (2023)

Viruses are prevalent in non-ventilated hospital-acquired pneumonia
por: Shorr, Andrew F., et al.
Publicado: (2017)

Characteristics of doripenem: a new broad-spectrum antibiotic
por: Alvarez-Lerma, Francisco, et al.
Publicado: (2009)

How to avoid microaspiration? A key element for the prevention of ventilator-associated pneumonia in intubated ICU patients
por: Blot, Stijn I, et al.
Publicado: (2014)

1477. Impact Of Resistance Thresholds On Mortality In Hospital-Acquired And Ventilator-Associated Pneumonia
por: Mazi, Patrick B, et al.
Publicado: (2020)

Pleural fluid penetration of moxifloxacin and doripenem: An experimental model of empyema
por: Calik, Mustafa, et al.
Publicado: (2019)

Isotherm data for adsorption of amoxicillin, ampicillin, and doripenem onto bentonite
por: Yeo, Jason Yi Juang, et al.
Publicado: (2023)

Effects of Various Antibiotics Alone or in Combination with Doripenem against Klebsiella pneumoniae Strains Isolated in an Intensive Care Unit
por: Ozbek Celik, Berna, et al.
Publicado: (2014)

Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study
por: Trupka, Tracy, et al.
Publicado: (2017)

Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections
por: Lo, Tze Shien, et al.
Publicado: (2009)

In Vitro Antibacterial Interaction of Doripenem and Amikacin against Multidrug-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates
por: Loho, Tonny, et al.
Publicado: (2018)

Pneumonia in the Hospital Setting
por: Kollef, Marin H.
Publicado: (2005)

Association of doripenem resistance with OXA-type carbapenemases in Acinetobacter baumannii isolates
por: Terzi, Huseyin-Agah, et al.
Publicado: (2016)

Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit
por: Nonoshita, Ko, et al.
Publicado: (2020)

A meta-analysis of efficacy and safety of doripenem for treating bacterial infections
por: Qu, Xiao-Yu, et al.
Publicado: (2015)

Continuous high-dose infusion of doripenem in a pneumonia patient infected by carbapenem-resistant Pseudomonas aeruginosa: a case report
por: Oda, Kazutaka, et al.
Publicado: (2019)

Fingolimod Promotes Antibacterial Effect of Doripenem against Carbapenem-Resistant Escherichia coli
por: Jin, Hye-Won, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations
por: Wang, Yu, et al.
Publicado: (2022)

Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia
por: Shorr, Andrew F, et al.
Publicado: (2006)

The win ratio method: a novel hierarchical endpoint for pneumonia trials in patients on mechanical ventilation
por: Montgomery, A, et al.
Publicado: (2014)

1233 A Comparison of National Healthcare Safety Network (NHSN) Ventilator Associated Pneumonia (VAP) and Ventilator Associated Event (VAE) Definitions
por: Mcmullen, Kathleen, et al.
Publicado: (2014)

Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
por: Walsh, Fiona
Publicado: (2007)

Doripenem Dosing Recommendations for Critically Ill Patients Receiving Continuous Renal Replacement Therapy
por: Samtani, Mahesh N., et al.
Publicado: (2012)

Clinical Experience of Patients Receiving Doripenem-Containing Regimens for the Treatment of Healthcare-Associated Infections
por: Chao, Chien-Ming, et al.
Publicado: (2016)

Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens
por: Oesterreicher, Zoe, et al.
Publicado: (2017)

Structural Analysis of The OXA-48 Carbapenemase Bound to A “Poor” Carbapenem Substrate, Doripenem
por: Papp-Wallace, Krisztina M., et al.
Publicado: (2019)

2586. Comparison of Antimicrobial Regimens for Critically Ill Patients with Suspected or Confirmed Hospital-Acquired or Ventilator-Associated Pneumonia: A Retrospective, Cohort Study
por: Kosharek, Abigail, et al.
Publicado: (2023)

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
por: Timsit, Jean-François, et al.
Publicado: (2021)

Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2010)

166 Rapid MRSA PCR on Respiratory Specimens from Ventilated Patients with Suspected Pneumonia: A Potential Tool for Antimicrobial Stewardship
por: Trevino, Sergio E., et al.
Publicado: (2014)

Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial
por: Martin-Loeches, Ignacio, et al.
Publicado: (2023)

In vitro Activity of Pentamidine Alone and in Combination With Aminoglycosides, Tigecycline, Rifampicin, and Doripenem Against Clinical Strains of Carbapenemase-Producing and/or Colistin-Resistant Enterobacteriaceae
por: Cebrero-Cangueiro, Tania, et al.
Publicado: (2018)

Bench-to-bedside review: Antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit
por: Kollef, Marin H
Publicado: (2005)

In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model
por: Vossen, M G, et al.
Publicado: (2021)

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
por: Wagenlehner, Florian M., et al.
Publicado: (2016)

Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem
por: Kollef, Marin H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v89ab75lkl6vs8a7rgu2f8uesq